Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease

References

• Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart disease and stroke statistics—2020 update: a report from the American heart association. Circulation. 2020;141(9):e139–11. doi:10.1161/CIR.0000000000000757.
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227–34. doi:10.1038/nm1102-1227.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33. doi:10.1016/s0140-6736(01)05701-4.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. doi:10.1056/NEJMoa010746.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–51. doi:10.1016/j.jacc.2004.09.067.
   PubMed Web of Science ®Google Scholar
• Trenk D, Zolk O, Fromm MF, Neumann FJ, Hochholzer W. Personalizing antiplatelet therapy with clopidogrel. Clin Pharmacol Ther. 2012;92:476–85. doi:10.1038/clpt.2012.133.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73. doi:10.1016/j.jacc.2013.07.101.
   PubMed Web of Science ®Google Scholar
• Trenk D, Kristensen SD, Hochholzer W, Neumann FJ. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thromb Haemost. 2013;109(05):834–45. doi:10.1160/TH12-08-0588.
   PubMedGoogle Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 2011;124(10):1132–7. doi:10.1161/CIRCULATIONAHA.111.029165.
   PubMed Web of Science ®Google Scholar
• Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657–66. doi:10.1016/j.jacc.2006.10.050.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–23. doi:10.1016/S0140-6736(13)61170-8.
   PubMed Web of Science ®Google Scholar
• Park MW, Her SH, Kim CJ, SunCho J, Park GM, Kim TS, Choi YS, Park CS, Koh YS, Park HJ, et al. Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genet Med. 2016;18(8):833–41. doi:10.1038/gim.2015.171.
   PubMed Web of Science ®Google Scholar
• Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013;106(10):517–27. doi:10.1016/j.acvd.2013.06.055.
   PubMed Web of Science ®Google Scholar
• Tantray JA, Reddy KP, Jamil K, Kumar YS. Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy. Int J Cardiol. 2017;229:113–18. doi:10.1016/j.ijcard.2016.11.217.
   PubMed Web of Science ®Google Scholar
• Sun H, Qu Q, Chen ZF, Tan SL, Zhou HJ, Qu J, Chen H. Impact of CYP2C19 variants on clinical efficacy of clopidogrel and 1-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention. Front Pharmacol. 2016;7:453. doi:10.3389/fphar.2016.00453.
   PubMed Web of Science ®Google Scholar
• Wang JY, Zhang YJ, Li H, Hu XL, Li MP, Song PY, Ma QL, Peng LM, Chen XP. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. Gene. 2018;678:226–32. doi:10.1016/j.gene.2018.08.027.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang YJ, Li MP, Hu XL, Song PY, Peng LM, Ma QL, Tang J, Zhang W, Chen XP. Association of N6AMT1 rs2254638 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. Front Pharmacol. 2018;9:1039. doi:10.3389/fphar.2018.01039.
   PubMed Web of Science ®Google Scholar
• Zhu KX, Song PY, He L, Li MP, Du YX, Ma QL, Peng LM, Chen XP. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. Eur J Clin Pharmacol. 2021;77(3):359–68. doi:10.1007/s00228-020-03024-6.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57. doi:10.1001/jama.2009.1232.
   PubMed Web of Science ®Google Scholar
• Zhong WP, Wu H, Chen JY, Li XX, Lin HM, Zhang B, Zhang ZW, Ma DL, Sun S, Li HP, et al. Genomewide association study identifies novel genetic loci that modify antiplatelet effects and pharmacokinetics of clopidogrel. Clin Pharmacol Ther. 2017;101(6):791–802. doi:10.1002/cpt.589.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Buttner HJ, Neumann FJ. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55(22):2427–34. doi:10.1016/j.jacc.2010.02.031.
   PubMed Web of Science ®Google Scholar
• Stratz C, Bomicke T, Younas I, Kittel A, Amann M, Valina CM, Nuhrenberg T, Trenk D, Neumann FJ, Hochholzer W. Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy. J Am Coll Cardiol. 2016;68(3):286–93. doi:10.1016/j.jacc.2016.04.056.
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRnas. Nature. 2008;455(7209):58–63. doi:10.1038/nature07228.
   PubMed Web of Science ®Google Scholar
• Bai YP, Zhang JX, Sun Q, Zhou JP, Luo JM, He LF, Lin XC, Zhu LP, Wu WZ, Wang ZY, et al. Induction of microRNA-199 by nitric oxide in endothelial cells is required for nitrovasodilator resistance via targeting of prostaglandin I2 synthase. Circulation. 2018;138(4):397–411. doi:10.1161/CIRCULATIONAHA.117.029206.
   PubMed Web of Science ®Google Scholar
• Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley SR, et al. Circulating microRnas as novel biomarkers for platelet activation. Circ Res. 2013;112(4):595–600. doi:10.1161/CIRCRESAHA.111.300539.
   PubMed Web of Science ®Google Scholar
• Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 2016;68(23):2577–84. doi:10.1016/j.jacc.2016.09.945.
   PubMed Web of Science ®Google Scholar
• Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton AC, Armstrong PC, et al. Association of MicroRNAs and YRNAs with platelet function. Circ Res. 2016;118(3):420–32. doi:10.1161/CIRCRESAHA.114.305663.
   PubMed Web of Science ®Google Scholar
• Pedersen OB, Hvas AM, Grove EL, Larsen SB, Pasalic L, Kristensen SD, Nissen PH. Association of whole blood microRNA expression with platelet function and turnover in patients with coronary artery disease. Thromb Res. 2022;211:98–105. doi:10.1016/j.thromres.2022.01.026.
   PubMed Web of Science ®Google Scholar
• Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16(9):961–6. doi:10.1038/nsmb.1651.
   PubMed Web of Science ®Google Scholar
• Shi R, Ge L, Zhou X, Ji WJ, Lu RY, Zhang YY, Zeng S, Liu X, Zhao JH, Zhang WC, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res. 2013;131(6):508–13. doi:10.1016/j.thromres.2013.02.015.
   PubMed Web of Science ®Google Scholar
• Liu YL, Hu XL, Song PY, Li H, Li MP, Du YX, Li MY, Ma QL, Peng LM, Song MY, et al. Influence of GAS5/MicroRNA-223-3p/P2Y12 axis on clopidogrel response in coronary artery disease. J Am Heart Assoc. 2021;10(21):e021129. doi:10.1161/JAHA.121.021129.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Zhou X, Ji WJ, Shi R, Lu RY, Li JL, Yang GH, Luo T, Zhang JQ, Zhao JH, et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis. 2014;38(1):65–72. doi:10.1007/s11239-013-1022-9.
   PubMed Web of Science ®Google Scholar
• Chyrchel B, Toton-Zuranska J, Kruszelnicka O, Chyrchel M, Mielecki W, Kolton-Wroz M, Wolkow P, Surdacki A. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets. 2015;26(6):593–7. doi:10.3109/09537104.2014.974527.
   PubMed Web of Science ®Google Scholar
• Chen S, Qi X, Chen H, Li M, Gu J, Liu C, Xue H, Wang L, Geng Y, Qi P, et al. Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. Exp Ther Med. 2016;12(1):518–24. doi:10.3892/etm.2016.3278.
   PubMed Web of Science ®Google Scholar
• Peng L, Liu J, Qin L, Liu J, Xi S, Lu C, Yin T. Interaction between platelet-derived microRnas and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS. Thromb Res. 2017;157:97–102. doi:10.1016/j.thromres.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Zhou WL, Mo ZZ, Xiao FY, Dai W, Wang G, Zhou G, Zhang W, Chen BL. MicroRNA-605 rs2043556 polymorphisms affect clopidogrel therapy through modulation of CYP2B6 and P2RY12 in acute coronary syndrome patients. Platelets. 2020;31(7):897–905. doi:10.1080/09537104.2019.1696455.
   PubMed Web of Science ®Google Scholar
• Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3(1):85–92. doi:10.1111/j.1538-7836.2004.01063.x.
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5(8):1630–6. doi:10.1111/j.1538-7836.2007.02609.x.
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51(14):1404–11. doi:10.1016/j.jacc.2007.12.044.
   PubMed Web of Science ®Google Scholar
• Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol. 2011;58(5):467–73. doi:10.1016/j.jacc.2011.04.017.
   PubMed Web of Science ®Google Scholar
• Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, Lopez JA, Yang L, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011;117(19):5189–97. doi:10.1182/blood-2010-09-299719.
   PubMed Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30(14):1744–52. doi:10.1093/eurheartj/ehp157.
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306(20):2221–8. doi:10.1001/jama.2011.1703.
   PubMed Web of Science ®Google Scholar
• Woulfe DS. Akt signaling in platelets and thrombosis. Expert Rev Hematol. 2010;3(1):81–91. doi:10.1586/ehm.09.75.
   PubMed Web of Science ®Google Scholar
• Rane S, He M, Sayed D, Yan L, Vatner D, Abdellatif M. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell Signal. 2010;22(7):1054–62. doi:10.1016/j.cellsig.2010.02.008.
   PubMed Web of Science ®Google Scholar
• Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle. 2010;9(16):3213–7. doi:10.4161/cc.9.16.12634.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–16. doi:10.1016/j.jacc.2006.11.044.
   PubMed Web of Science ®Google Scholar
• Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147–66. doi:10.1007/s40262-014-0230-6.
   PubMed Web of Science ®Google Scholar